Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

ViGeneron, a Germany-based gene therapy spinout of Ludwig Maximilian University of Munich, on Thursday closed a series A round of undisclosed size co-led by pharmaceutical firm WuXi AppTec and venture capital firm Sequoia Capital China. The money will help progress two platforms targeting ophthalmological conditions: the first, dubbed vgAAV, is a viral vector designed to effectively cross biological barriers within the retina to reach a range of target cells, while a second technique called Revert would restructure larger genes as vgAAV-compatible proteins using RNA processing. The platforms will underpin development on intravitreal injections for two unspecified eye diseases where no approved medical treatments are currently available. ViGeneron was established in 2017 by co-founders including Stylianos Michalakis, a professor in the Department of Ophthalmology, and Martin Biel from the Center for Drug Research in the Department of Pharmacy.